Effect of morning versus evening dosing of diltiazem on myocardial ischemia detected by ambulatory electrocardiographic monitoring in chronic stable angina pectoris

American Journal of Cardiology

Volumn 80, Issue 4, 1997, Pages 421-425

  Deedwania, Prakash C ^a,b,c,d   Pool, Peter E ^a,b,c,d   Thadani, Udho ^a,b,c,d   Eff, Jack ^a,b,c,d  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b Reno Cardiology Research Laboratory   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DILTIAZEM;

AMBULATORY MONITORING; ANGINA PECTORIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; ELECTROCARDIOGRAM; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ANALYSIS OF VARIANCE; ANGINA PECTORIS; CHRONIC DISEASE; CIRCADIAN RHYTHM; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DILTIAZEM; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY, AMBULATORY; HUMANS; MYOCARDIAL ISCHEMIA; VASODILATOR AGENTS;

EID: 0030842712     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)00389-5     Document Type: Article

References (28)

1. Pepine CJ. Circadian variation in myocardial ischemia. Implications for management. J Am Med Assoc. 265:1991;386-390.
2. Pool PE. Diltiazem. Messerli FH. Cardiovascular Drug Therapy. 1990;939-974 W. B. Saunders Co, Philadelphia.
3. Pool PE, Herron JM, Rosenblatt S, Reeves RL, Nappi JM, Staker LV, Dipette DJ, Evans RR. Sustained-release diltiazem: duration of antihypertensive effect. J Clin Pharmacol. 29:1989;533-537.
4. Pool PE, Massie BM, Venkataraman K, Hirsch AT, Samant DR, Seagreen SC, Gaw J, Salel AF, Tubau JF. Diltiazem as monotherapy for systemic hypertension: a multicenter, randomized, placebo-controlled trial. Am J Cardiol. 57:1986;212-217.
5. Pool PE, Nappi JM, Weber MA. Antihypertensive monotherapy with tablet (prompt-release) diltiazem: multicenter controlled trials. Cardiovasc Drug Ther. 4:1990;1089-1096.
6. Théroux P, Baird M, Juneau M, Warnica W, Klinke P, Kostuk W, Pflugfelder P, Lavallee E, Chin C, Dempsey E, Grace M, Lalonda Y, Waters D. Effect of diltiazem on symptomatic and asymptomatic episodes of ST segment depression occurring during daily life and during exercise. Circulation. 84:1991;15-22.
7. Portegies MCM, Sijbring P, Göbel EJAM, Viersma JW, Lie KI. Efficacy of metoprolol and diltiazem in treating silent myocardial ischemia. Am J Cardiol. 74:1994;1095-1098.
8. Stone PH, Gibson RS, Glasser SP, DeWood MA, Parker JD, Kawanishi DT, Crawford MH, Messineo FC, Shook TL, Raby K, Curtis DG, Hoop RS, Young PM, Braunwald E. Comparison of propranolol, diltiazem, and nifedipine in the treatment of ambulatory ischemia in patients with stable angina. Differential effects on ambulatory ischemia, exercise performance, and anginal symptoms. Circulation. 82:1990;1962-1972.
9. Ziemniak J, Colligon I, Heald D. Steady-state dose proportionality of a once-a-day sustained-release diltiazem hydrochloride formulation in healthy subjects. Clin Ther. 14:1992;158-165.
10. Bruce RA. Exercise testing of patients with coronary heart disease. Principles and normal standards of evaluation. Ann Clin Res. 3:1971;323-332.
11. Pepine C, Singh B, Gibson R, Kent K. Report of group IV: management options. In: Cohn PF, Kannel WB, eds. Recognition, pathogenesis, and management options in silent coronary artery disease. Circulation 1987;75(suppl II):II-52-II-53.
12. Haycock KA, Roth J, Gagnon J, Finzer WF, Soper C. StatView (v. 4.01). 1992;Abacus Concepts, Inc, Berkeley, CA.
13. Muller JE, Abela GS, Nesto RW, Tofler GH. Triggers, acute risk factors and vulnerable plaques: the lexicon of a new frontier. J Am Coll Cardiol. 23:1994;809-813.
14. Davies RF, Habibi H, Klinke WP, Dessain P, Nadeau C, Phaneuf DC, Lepage S, Raman S, Herbert M, Foris K, Linden W, Buttars JA. Effect of amlodipine, atenolol and their combination on myocardial ischemia during treadmill exercise and ambulatory monitoring. J Am Coll Cardiol. 25:1995;619-625.
15. Pepine CJ, Cohn PF, Deedwania PC, Gibson RS, Handberg E, Hill JA, Miller E, Marks RG, Thadani U. Effects of treatment on outcome in mildly symptomatic patients with ischemia during daily life: the atenolol silent ischemia study (ASIST). Circulation. 90:1994;762-768.
16. von Arnim T. Medical treatment to reduce total ischemic burden: total ischemic burden bisoprolol study (TIBBS), a multicenter trial comparing bisoprolol and nifedipine. J Am Coll Cardiol. 25:1995;231-238.
17. Ardissino D, Savonitto S, Egstrup K, Marraccini P, Slavich G, Rosenfeld M, Feruglio GA, Roncarolo P, Giordano MP, Wahlquist I, Rhenquist N, Barberis P, Specchia G, L'Abbate A. Transient myocardial ischemia during daily life in rest and exertional angina pectoris and comparison of effectiveness of metoprolol versus nifedipine. Am J Cardiol. 67:1991;946-952.
18. Andrews TC, Fenton T, Toyosaki N, Glasser SP, Young PM, MacCallum G, Gibson RS, Shook TL, Stone PH. Subsets of ambulatory myocardial ischemia based on heart rate activity: circadian distribution and response to anti-ischemic medication. Circulation. 88:1993;92-100.
19. Parmley WW, Nesto RW, Singh BN, Deanfield J, Gottlieb SO. Attenuation of the circadian patterns of myocardial ischemia with nifedipine GITS in patients with chronic stable angina. J Am Coll Cardiol. 19:1992;1380-1389.
20. Cohn PF, Vetrovec GW, Nesto R, Gerber FR. The nifedipine-total Ischemia Awareness Program: a national survey of painful and painless myocardial ischemia including results of antiischemic therapy. Am J Cardiol. 63:1989;534-539.
21. Kawanishi DT, Reid CL, Morrison EC, Rahimtoola SH. Response of angina and ischemia to long-term treatment in patients with chronic stable angina: a double-blind randomized individualized dosing trial of nifedipine, propranolol and their combination. J Am Coll Cardiol. 19:1992;409-417.
22. Deedwania PC. Increased demand versus reduced supply and the circadian variations in ambulatory myocardial ischemia: therapeutic implications. Circulation. 88:1993;328-331.
23. Panza JA, Diodati JG, Callahan TS, Epstein SE, Quyyumi AA. Role of increases in heart rate in determining the occurrence and frequency of myocardial ischemia during daily life in patients with stable coronary artery disease. J Am Coll Cardiol. 20:1992;1092-1098.
24. Quyyumi AA, Panza JA, Diodati JG, Lakatos E, Epstein SE. Circadian variation in ischemic threshold: a mechanism underlying the circadian variation in ischemic events. Circulation. 86:1992;22-28.
25. Panza JA, Epstein SE, Quyyumi AA. Circadian variation in vascular tone and its relation to alpha-sympathetic vasoconstrictor activity. New Engl J Med. 325:1991;986-990.
26. Parker JD, Testa MA, Jimenez AH, Tofler GH, Muller JE, Parker JO, Stone PH. Morning increase in ambulatory ischemia in patients with stable coronary artery disease: importance of physical activity and increased cardiac demand. Circulation. 89:1994;604-614.
27. Thadani U, Glasser S, Bittar N, Beach CL. Dose-response evaluation of once-daily therapy with a new formulation of diltiazem for stable angina pectoris. Am J Cardiol. 74:1994;9-17.
28. Zarich S, Waxman S, Freeman RT, Mittleman M, Hegarty P, Nesto RW. Effect of autonomic nervous system dysfunction on the circadian pattern of myocardial ischemia in diabetes mellitus. J Am Coll Cardiol. 24:1994;956-962.